DRD5 Gene — Dopamine Receptor D5

DRD5 Gene — Dopamine Receptor D5

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">dr5</th>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>5q35.1</td>
</tr>
<tr>
<td class="label">Amino acids</td>
<td>446</td>
</tr>
<tr>
<td class="label">D5 has 31 additional residues in C-terminus</td>
<td>| D5 has higher basal activity (constitutive activity)</td>
</tr>
<tr>
<td class="label">D5 has higher dopamine affinity (~10-fold)</td>
<td>| D5 mRNA shows more widespread brain distribution</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/breast-cancer" style="color:#ef9a9a">Breast Cancer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/lymphoma" style="color:#ef9a9a">Lymphoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">72 edges</a></td>
</tr>
</table>

Overview

DRD5 Gene — Dopamine Receptor D5

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">dr5</th>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>5q35.1</td>
</tr>
<tr>
<td class="label">Amino acids</td>
<td>446</td>
</tr>
<tr>
<td class="label">D5 has 31 additional residues in C-terminus</td>
<td>| D5 has higher basal activity (constitutive activity)</td>
</tr>
<tr>
<td class="label">D5 has higher dopamine affinity (~10-fold)</td>
<td>| D5 mRNA shows more widespread brain distribution</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/breast-cancer" style="color:#ef9a9a">Breast Cancer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/lymphoma" style="color:#ef9a9a">Lymphoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">72 edges</a></td>
</tr>
</table>

Overview

DRD5 (Dopamine Receptor D5, NCBI Gene ID: 1816, OMIM: [126453](https://www.omim.org/entry/126453), UniProt: [P21918](https://www.uniprot.org/uniprot/P21918), Ensembl: [ENSG00000169679](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169679)) encodes the D5 dopamine receptor, a G protein-coupled receptor (GPCR) belonging to the D1-like family of dopamine receptors. DRD5 exhibits the highest dopamine affinity among all dopamine receptor subtypes and is coupled primarily to Gαs proteins that stimulate adenylyl cyclase[@sunahara1991]. Located on chromosome 4p16.1, DRD5 is expressed broadly across the brain with highest densities in the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), [striatum](/brain-regions/striatum), and [substantia nigra](/brain-regions/substantia-nigra). The receptor plays essential roles in cognitive function, motor control, circadian rhythm regulation, and reward-motivated behavior. Dysregulation of DRD5 signaling is implicated in [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), [schizophrenia](/diseases/schizophrenia), and various movement disorders[@chen2019].

Unlike D2-like receptors (DRD2, DRD3, DRD4) which couple to Gαi and inhibit cAMP production, D5 receptors activate Gαs-mediated signaling cascades that increase intracellular cAMP, activate protein kinase A (PKA), and modulate downstream effectors including ion channels, transcription factors, and synaptic proteins[@sibley1999]. This signaling profile positions DRD5 as a key modulator of excitatory dopaminergic responses in neural circuits.

Gene Structure and Protein Architecture

Genomic Organization

The human DRD5 gene spans approximately 4.3 kb on chromosome 4p16.1 and consists of 2 coding exons. The gene encodes a 477 amino acid protein with a molecular weight of approximately 52.9 kDa. DRD5 is closely linked to DRD1 on chromosome 4, suggesting a common evolutionary origin through gene duplication.

Protein Structure

The D5 receptor is a typical GPCR with seven transmembrane helices (TM1-TM7):

• N-terminal extracellular domain: Contains glycosylation sites, involved in ligand binding
• Transmembrane domains (TM1-TM7): Form the binding pocket for dopamine and synthetic ligands
• Three extracellular loops (ECL1-ECL3): Modulate ligand access and receptor conformation
• Three intracellular loops (ICL1-ICL3): Couple to G proteins and contain regulatory phosphorylation sites
• C-terminal intracellular tail: Contains serine/threonine residues for PKA phosphorylation and PDZ-binding motifs

Comparison with D1 Family

Molecular Function and Signal Transduction

G Protein Coupling and Signaling Pathways

DRD5 couples primarily to Gαs proteins, initiating the following cascade[@berthaus2004]:

Primary signaling (Gs-coupled):

Secondary signaling pathways:

• Gβγ signaling: Gβγ subunits can activate phospholipase C-β (PLC-β)
• MAPK pathway: D5 receptors can activate ERK1/2 through PI3K
• Calcium signaling: D5-mediated depolarization affects voltage-gated calcium channels

Constitutive Activity

A distinctive feature of DRD5 is its significant constitutive (ligand-independent) activity[@greengard2001]:

• The receptor adopts an active conformation even without dopamine bound
• Results in basal cAMP production in the absence of ligand
• Makes the receptor a tonic signal generator, not just a response amplifier
• Has implications for drug development — neutral antagonists vs. inverse agonists

Signal Termination

Signal is terminated through multiple mechanisms:

• Receptor internalization: β-arrestin-mediated endocytosis
• Phosphorylation: GRKs phosphorylate the receptor, uncoupling from G proteins
• Desensitization: PKA-mediated phosphorylation reduces coupling efficiency
• Receptor downregulation: Prolonged agonist exposure reduces receptor density

Brain Expression and Localization

Regional Distribution

DRD5 shows a broader anatomical distribution than DRD1[@richfield1999]:

High expression regions:

• Cerebral cortex: Particularly in prefrontal cortex (layer 5 pyramidal neurons)
• Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
• Striatum: Co-localizes with DRD1 in direct pathway medium spiny neurons
• Substantia nigra pars compacta: Dopaminergic neurons (autoreceptor function)
• Dentate nucleus of cerebellum: Deep cerebellar nucleus neurons

• Globus pallidus (external segment): GPe neurons
• Thalamus: Specific relay nuclei
• Hypothalamus: Arcuate nucleus and periventricular regions
• Superior colliculus: Layers involved in visual processing

• Amygdala: Scattered expression in central nucleus
• Brainstem: Reticular formation areas

Subcellular Localization

DRD5 is primarily localized to:

• Dendritic shafts and spines: Post-synaptic density of excitatory synapses
• Somatic plasma membrane: Perisynaptic regions
• Axon terminals: Presynaptic localization (some neurons — autoreceptor)
• Intracellular vesicles: Trafficking between endosomes and plasma membrane

Cell Type Specificity

Within brain regions, DRD5 is expressed in:

• Excitatory glutamatergic neurons: Pyramidal cells of cortex and hippocampus
• Medium spiny neurons (MSNs): Striatal GABAergic neurons of the direct pathway
• Dopaminergic neurons: Nigral neurons (atypical — usually D2 serves as autoreceptor)
• Interneurons: Some parvalbumin-positive basket cells in cortex

Physiological Roles

Motor Control

DRD5 plays critical roles in basal ganglia circuitry[@hanley2010]:

Direct pathway activation (with DRD1):
Cortex → Striatum (D1/D5 MSNs) → GPi/SNr → Thalamus → Cortex
↑ D1/D5 activation inhibits indirect pathway, facilitates movement

D1/D5 receptor activation on direct pathway MSNs:

• Excites neurons projecting to internal segment of globus pallidus (GPi)
• Inhibits GPi output to thalamus
• Disinhibits thalamocortical neurons
• Facilitates initiated movements

• Reduced direct pathway activity
• Excessive indirect pathway inhibition
• Movement initiation failure (bradykinesia)

Cognitive Function

DRD5 modulates several cognitive domains:

Working memory:

• Prefrontal cortex D5 receptors enhance persistent firing of delay cells
• Required for maintaining information across delay periods
• D5/D1 activation in PFC layers 2/3 and 5 supports spatial working memory

• D5 receptor activity in anterior cingulate cortex
• Supports task-switching and conflict monitoring
• D5 polymorphisms associated with attention deficit symptoms

• Hippocampal D5 receptors contribute to long-term potentiation (LTP)
• D5 activation enhances NMDA receptor function
• Contributes to reward learning and memory consolidation

Circadian Rhythm

DRD5 is expressed in the suprachiasmatic nucleus (SCN) and modulates circadian clock function:

• D5/D1 receptors in SCN neurons respond to dopamine released from the intergeniculate leaflet
• Controls photic and non-photic entrainment of the circadian clock
• D5 signaling affects clock gene expression (PER1, PER2)
• Implications for sleep disorders and clock-related neurodegeneration

Reward and Motivation

While DRD5 is not the primary reward receptor (DRD1 and DRD2 dominate mesolimbic reward), DRD5 contributes:

• Reinforcement of reward-related behaviors
• Modulation of reward magnitude
• Interaction with emotional processing circuits

Disease Associations

Parkinson's Disease

DRD5 plays complex roles in [Parkinson's disease](/diseases/parkinsons-disease)[@mishina2012]:

Pathophysiological involvement:

• D5 receptors are relatively spared compared to D2 receptors in PD
• Remaining D5 activity contributes to motor reserve
• D5/D1 heterodimerization may influence response to levodopa therapy

• D1/D5 agonists (bromocriptine, pergolide) used in early PD
• D1/D5 receptor density affects levodopa response duration
• Wearing-off phenomena may involve D5 receptor desensitization

• DRD5 polymorphisms have been investigated for PD risk
• Some studies suggest DRD5 variants modify PD susceptibility
• Haplotype analysis reveals modest but reproducible associations

Alzheimer's Disease

Emerging evidence links DRD5 to [Alzheimer's disease](/diseases/alzheimers-disease) pathology[@yang2019]:

Mechanisms:

• Dopaminergic dysfunction occurs early in AD, before motor symptoms
• D5 receptors modulate hippocampal plasticity — affected in AD
• D5 signaling interacts with amyloid-beta and tau pathology

• D5/D1 dysfunction contributes to working memory deficits in AD
• Cholinergic-dopaminergic interaction in memory circuits
• D5 receptor density declines with age and AD progression

• Dopamine replacement shows modest cognitive benefits in AD
• D1/D5 agonists being investigated for AD cognitive symptoms
• Combination with cholinesterase inhibitors under study

Schizophrenia

DRD5 is implicated in [schizophrenia](/diseases/schizophrenia) pathophysiology[@luo2018]:

Dopamine hypothesis refinement:

• Hyperactive dopamine transmission in mesolimbic pathway
• D2 receptors mediate positive symptoms (hallucinations, delusions)
• D1/D5 dysfunction in prefrontal cortex mediates negative symptoms and cognitive deficits

• Reduced D1/D5 signaling in PFC causes working memory deficits
• Low D1/D5 tone may underlie negative symptoms (avolition, flat affect)
• Genetic variants affecting D5 expression modify schizophrenia risk

• All antipsychotics block D2 receptors primarily
• Some atypical antipsychotics (clozapine, quetiapine) have higher D5:D2 affinity ratios
• May explain superior efficacy for negative and cognitive symptoms

Movement Disorders

Dystonia:

• D5 receptor mutations associated with focal dystonia
• DRD5 variants in writer's cramp and blepharospasm
• D1/D5 dysfunction in basal ganglia causes excessive involuntary movements

• DRD5 polymorphisms associated with tic disorders
• D5/D1 hyperactivity in cortico-striato-thalamo-cortical circuits
• D1/D5 antagonists partially reduce tic severity

• D5/D1 receptor loss in striatum correlates with chorea severity
• Early HD shows preserved D5/D1; late HD shows significant loss

Molecular Mechanisms

Receptor Dimerization

DRD5 forms heteromers with other GPCRs, creating unique signaling properties[@seutin2005]:

• DRD5-DRD1 heteromers: Physical interaction between D1 and D5 creates a "super-receptor" with enhanced G-protein coupling and biased signaling
• DRD5-DRD2 complexes: In some neurons, D5-D2 complexes modulate cross-talk between D1-like and D2-like signaling
• A2A-D5 interactions: Adenosine A2A and D5 receptors form functional heteromers, affecting striatal signaling

Interactions with Other Proteins

DRD5 interacts with numerous scaffolding and signaling proteins:

• β-arrestin 1/2: Internalization, biased signaling
• AKAP150/79: Targeting PKA to the receptor complex
• DARPP-32: Key signaling hub in striatal neurons
• PSD-95 family: Postsynaptic density anchoring
• RGS proteins: Regulators of G protein signaling

DARPP-32 Pathway

DRD5 activation in striatal neurons activates the DARPP-32 cascade[@greengard2001]:

Therapeutic Targeting

Agonists

Non-selective D1/D5 agonists:

• Dihydrexidine (DAR-0100): Full D1/D5 agonist, investigated for PD and schizophrenia cognitive symptoms
• SKF81297: Research tool, high D1/D5 selectivity
• A-77636: D1/D5 agonist with long duration of action

• D1/D5 agonists cause significant hypotension (vasodilatory effect)
• CNS penetration is challenging — many compounds are substrates for P-glycoprotein
• Tachyphylaxis develops with continued use

Antagonists

Clinical antipsychotics with D1/D5 activity:

• Clozapine: Highest D5:D2 affinity ratio among approved drugs
• Quetiapine: Blocks D5 along with D2; better cognitive profile
• Fluphenazine: High D1/D5 blockade

• SCH23390: First selective D1/D5 antagonist, research standard
• SKL83556: High-affinity D1/D5 antagonist with CNS penetration

Allosteric Modulators

• PAI-1 (D1/D5 positive allosteric modulator): Increases affinity for dopamine
• BBR-1: D1/D5 negative allosteric modulator

Genetic Variants and Polymorphisms

Common Variants

• rs77497769: Promoter variant affecting transcription
• rs6283: Missense variant (Pro310Leu) with reduced coupling efficiency
• rs2075652: Intron variant associated with schizophrenia in GWAS
• rs1800762: 5' UTR variant affecting translation

Rare Pathogenic Variants

• Benign hereditary chorea: Some DRD5 variants cause early-onset movement disorder
• Myoclonus-dystonia: Rare DRD5 mutations in some families
• Tourette syndrome: Rare DRD5 variants found in severe cases

Animal Models

Knockout Mice

Drd5 null mice:

• Viable and fertile — no developmental abnormalities
• Reduced locomotor response to D1/D5 agonists
• Impaired working memory in Morris water maze
• Altered circadian phase-shifting

• Forebrain-specific Drd5 KO reproduces cognitive phenotypes
• Striatal-specific KO affects motor learning

Transgenic Models

• DRD5 overexpression: Increases basal activity, causes hyperactivity
• Constitutively active DRD5: Mimics agonist stimulation without ligand

See Also

• [Dopamine Receptors](/entities/dopamine-receptors) — receptor family overview
• [DRD1 Gene](/genes/drd1) — closely related D1 receptor
• [DRD2 Gene](/genes/drd2) — D2 receptor, primary target in PD treatment
• [Parkinson's Disease](/diseases/parkinsons-disease) — PD and dopamine signaling
• [Alzheimer's Disease](/diseases/alzheimers-disease) — cognitive symptoms and dopamine
• [Schizophrenia](/diseases/schizophrenia) — dopamine hypothesis and treatment
• [Dopamine Signaling](/mechanisms/dopamine-signaling-pathway) — detailed signaling pathways
• [Basal Ganglia Circuits](/mechanisms/basal-ganglia-circuits) — motor control and disease
• [GPCR Signaling in Neurodegeneration](/mechanisms/gpcr-signaling-neurodegeneration) — GPCR mechanisms

External Links

• [NCBI Gene 1816](https://www.ncbi.nlm.nih.gov/gene/1816)
• [OMIM 126453](https://www.omim.org/entry/126453)
• [UniProt P21918](https://www.uniprot.org/uniprot/P21918)
• [Ensembl ENSG00000169679](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169679)
• [IUPHAR/BPS Guide to Pharmacology](https://www.guidetopharmacology.org/GRAC/ObjectDetailsForward?name=DRD5&objectClass=receptor)
• [GeneCards DRD5](https://www.genecards.org/cgi-bin/carddisp.pl?gene=DRD5)

Pathway Diagram

The following diagram shows the key molecular relationships involving DRD5 Gene — Dopamine Receptor D5 discovered through SciDEX knowledge graph analysis: